Shanghai RAAS Blood Products Co Ltd Class A - Asset Resilience Ratio
Shanghai RAAS Blood Products Co Ltd Class A (002252) has an Asset Resilience Ratio of 4.52% as of June 2024. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. Read Shanghai RAAS Blood Products Co Ltd Clas balance sheet liabilities for a breakdown of total debt and financial obligations.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2014–2023)
This chart shows how Shanghai RAAS Blood Products Co Ltd Class A's Asset Resilience Ratio has changed over time. See Shanghai RAAS Blood Products Co Ltd Clas book value and equity for net asset value and shareholders' equity analysis.
Liquid Assets Composition Over Time
This chart breaks down Shanghai RAAS Blood Products Co Ltd Class A's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For market capitalisation and broader financial context, see market value of Shanghai RAAS Blood Products Co Ltd Clas.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | CN¥0.00 | 0% |
| Short-term Investments | CN¥1.46 Billion | 4.52% |
| Total Liquid Assets | CN¥1.46 Billion | 4.52% |
Asset Resilience Insights
- Limited Liquidity: Shanghai RAAS Blood Products Co Ltd Class A maintains only 4.52% of assets in liquid form.
- This low level may indicate efficient asset utilization but could pose risks during economic downturns.
- The company has significant short-term investments, indicating active treasury management.
Shanghai RAAS Blood Products Co Ltd Class A Industry Peers by Asset Resilience Ratio
Compare Shanghai RAAS Blood Products Co Ltd Class A's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Merus BV
NASDAQ:MRUS |
Biotechnology | 29.69% |
|
Shanghai Allist Pharmaceuticals Co. Ltd. A
SHG:688578 |
Biotechnology | 30.29% |
|
Beijing Tiantan Biological Products Corp Ltd
SHG:600161 |
Biotechnology | 8.08% |
|
Beijing Hotgen Biotech Co Ltd
SHG:688068 |
Biotechnology | 20.87% |
|
Savara Inc
NASDAQ:SVRA |
Biotechnology | 76.71% |
|
Wuhan Hvsen Biotechnology Co Ltd
SHE:300871 |
Biotechnology | 9.59% |
|
Wecome Pharmaceutical Co Ltd
SHE:300878 |
Biotechnology | 0.67% |
|
Shanghai Shen Lian Biomedical Corp
SHG:688098 |
Biotechnology | 3.87% |
Annual Asset Resilience Ratio for Shanghai RAAS Blood Products Co Ltd Class A (2014–2023)
The table below shows the annual Asset Resilience Ratio data for Shanghai RAAS Blood Products Co Ltd Class A.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2023-12-31 | 0.62% | CN¥197.41 Million ≈ $28.89 Million |
CN¥31.93 Billion ≈ $4.67 Billion |
-0.16pp |
| 2022-12-31 | 0.78% | CN¥237.77 Million ≈ $34.79 Million |
CN¥30.46 Billion ≈ $4.46 Billion |
-0.02pp |
| 2021-12-31 | 0.81% | CN¥219.38 Million ≈ $32.10 Million |
CN¥27.24 Billion ≈ $3.99 Billion |
-0.22pp |
| 2020-12-31 | 1.03% | CN¥262.14 Million ≈ $38.36 Million |
CN¥25.49 Billion ≈ $3.73 Billion |
-1.46pp |
| 2019-12-31 | 2.49% | CN¥295.40 Million ≈ $43.23 Million |
CN¥11.85 Billion ≈ $1.73 Billion |
-0.38pp |
| 2018-12-31 | 2.87% | CN¥327.05 Million ≈ $47.86 Million |
CN¥11.39 Billion ≈ $1.67 Billion |
-18.82pp |
| 2017-12-31 | 21.70% | CN¥3.14 Billion ≈ $458.95 Million |
CN¥14.46 Billion ≈ $2.12 Billion |
+5.39pp |
| 2016-12-31 | 16.31% | CN¥2.16 Billion ≈ $315.65 Million |
CN¥13.23 Billion ≈ $1.94 Billion |
+2.35pp |
| 2015-12-31 | 13.96% | CN¥1.61 Billion ≈ $236.05 Million |
CN¥11.56 Billion ≈ $1.69 Billion |
+13.94pp |
| 2014-12-31 | 0.02% | CN¥2.00 Million ≈ $292.66K |
CN¥9.38 Billion ≈ $1.37 Billion |
-- |
About Shanghai RAAS Blood Products Co Ltd Class A
Shanghai RAAS Blood Products Co., Ltd. engages in the manufacture and sale of blood products in China. It offers human serum albumin, human intravenous immunoglobulin, human coagulation factor VIII, human prothrombin complex, human fibrinogen, human thrombin and human fibrin adhesive, human immunoglobulin, hepatitis B immunoglobulin, tetanus immunoglobulin, and rabies immunoglobulin products. The… Read more